Cargando…
Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors
Brain tumors represent a diverse spectrum of histology, biology, prognosis, and treatment options. Although MRI remains the gold standard for morphological tumor characterization, positron emission tomography (PET) can play a critical role in evaluating disease status. This article focuses on the us...
Autores principales: | Jung, Ji-hoon, Ahn, Byeong-Cheol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Brain Tumor Society; The Korean Society for Neuro-Oncology; The Korean Society for Pediatric Neuro-Oncology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212689/ https://www.ncbi.nlm.nih.gov/pubmed/30381916 http://dx.doi.org/10.14791/btrt.2018.6.e13 |
Ejemplares similares
-
Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma
por: Sachpekidis, Christos, et al.
Publicado: (2019) -
Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer
por: Sakulpisuti, Chaninart, et al.
Publicado: (2022) -
Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals()
por: Cai, Zhengxin, et al.
Publicado: (2013) -
Quality control of positron emission tomography radiopharmaceuticals: An institutional experience
por: Shukla, Jaya, et al.
Publicado: (2013) -
Positron emission tomography: Evolving modalities, radiopharmaceuticals and professional collaboration
por: Ayesa, Sally L., et al.
Publicado: (2022)